Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial to Evaluate the Protective Efficacy and Safety of a Therapeutic Vaccine, ASP0113, in Cytomegalovirus (CMV)-Seropositive Recipients Undergoing Allogeneic, Hematopoietic Cell Transplant (HCT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 Jun 2022
Price :
$35
*
At a glance
- Drugs VCL CB01 (Primary)
- Indications Cytomegalovirus infections
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms HELIOS
- Sponsors Astellas Pharma; Astellas Pharma Global Development
- 02 Apr 2022 This trial has been completed in Spain (Date of the global end of the trial : 01-Mar-2022), according to European Clinical Trials Database record.
- 22 Mar 2022 Status changed from active, no longer recruiting to completed.
- 30 Apr 2021 Planned End Date changed from 4 Mar 2022 to 31 Mar 2022.